C. Grace Yeh, Ph.D.

President and Chief Executive Officer Pharma Engine, Inc.

Dr. Grace Yeh founded PharmaEngine, Inc. (TWO: 4162) in 2003, one of the most eye-catching success stories emerging from Taiwan’s maturing biopharmaceutical sector. PharmaEngine is the first Taiwan-based company receiving the US FDA approval for a locally-developed oncology product, Onivyde®, as the standard of care for the treatment of metastatic pancreatic cancer and approved in major markets.

Prior to returning to Taiwan, she served in senior positions at Millennium Pharmaceuticals, LeukoSite, CytoMed, and T Cell Sciences, all based in Cambridge, MA, USA. Prior to joining the industry, she worked in academic research at INSERM (National Institutes of Health and Medical Research) in France; and Blond McIndoe Centre for Transplantation Biology in England. Dr. Yeh received her B.S. in Biology from Fu-Jen University, Taiwan, and her Ph.D. in Immunology from Medical University of South Carolina, USA.

•Dr. Yeh received her B.S. in Biology from Fu-Jen University, Taiwan, and her Ph.D. in Immunology from Medical University of South Carolina, USA.  She has over 70 peer-reviewed publications and 6 issued US patents.

•PharmaEngine focuses on developing new drugs for cancer and Asian prevalent diseases. The company has adopted the no research development only (NRDO) and networked pharma models. PharmaEngine has three corporate partners (Merrimack Pharmaceuticals, Inc., Cambridge, MA, USA; Nanobiotix S.A., Paris, France; and Guangzhou BeBetter Technology Co., Ltd., Guangzhou, China). The company has received numerous awards

. •About PharmaEngine Milestones and Awards:

•PharmaEngine has successfully developed Onivyde (irinotecan liposome injection) from preclinical to phase 2, and licensed it to Merrimack Pharmaceuticals, Inc.,  for US$220 million of milestone payments plus tiered royalties in 2011.

•IPO debuts on Taiwan GreTai Securities Market and begins trading under the ticker”4162.TT” on Sept. 18, 2012.

•Technology Transfer gold medal for PEP02 project received at the 2012 Taipei Biotech Award. •ONIVYDE wins the Gold Prize of the pharmaceutical and technology research bioaward given by Taiwan MOHW and MOEA.

•Onivyde was approved for the treatment of post-gemcitabine metastatic pancreatic cancer patients by the Taiwan FDA and the US FDA in Oct. 2015.

•Onivyde Receives European Marketing Authorization for the Treatment of Metastatic Adenocarcinoma of the Pancreas Following Gemcitabine Based Therapy.

•Go-Global gold medal for PEP02 project (Onivyde) at the 2016 Taipei Biotech Award.

• EY Entrepreneur of the Year in 2016.

MEDIA REPORT

http://www.chinatimes.com/newspapers/20161227000107-260207

http://www.chinatimes.com/newspapers/20160523000056-260202

http://mag.cnyes.com/Content/20121228/11433d267eed41fc8d2b3f23ae5e688a.shtml

https://www.managertoday.com.tw/articles/view/15415

Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.